IRIS
PAOLICELLI, DAMIANO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 5.692
EU - Europa 1.612
AS - Asia 851
SA - Sud America 92
AF - Africa 8
Continente sconosciuto - Info sul continente non disponibili 7
OC - Oceania 6
Totale 8.268
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.666
CN - Cina 452
RU - Federazione Russa 374
SE - Svezia 366
SG - Singapore 293
IT - Italia 277
DE - Germania 133
FI - Finlandia 112
UA - Ucraina 105
GB - Regno Unito 93
BR - Brasile 77
BE - Belgio 37
FR - Francia 36
ID - Indonesia 31
NL - Olanda 24
CA - Canada 21
VN - Vietnam 21
HK - Hong Kong 14
AT - Austria 12
IN - India 12
CZ - Repubblica Ceca 7
IR - Iran 6
LT - Lituania 6
SA - Arabia Saudita 6
AU - Australia 5
BD - Bangladesh 5
IE - Irlanda 5
AR - Argentina 4
EU - Europa 4
BG - Bulgaria 3
CL - Cile 3
EC - Ecuador 3
PT - Portogallo 3
UZ - Uzbekistan 3
VE - Venezuela 3
A1 - Anonimo 2
AL - Albania 2
BS - Bahamas 2
CH - Svizzera 2
DZ - Algeria 2
ES - Italia 2
GR - Grecia 2
IQ - Iraq 2
KZ - Kazakistan 2
MX - Messico 2
PL - Polonia 2
RO - Romania 2
TN - Tunisia 2
ZA - Sudafrica 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AE - Emirati Arabi Uniti 1
CO - Colombia 1
DK - Danimarca 1
EE - Estonia 1
EG - Egitto 1
HR - Croazia 1
IS - Islanda 1
JP - Giappone 1
LB - Libano 1
LV - Lettonia 1
MA - Marocco 1
MK - Macedonia 1
NO - Norvegia 1
NZ - Nuova Zelanda 1
PA - Panama 1
PY - Paraguay 1
TR - Turchia 1
Totale 8.268
Salva come PNG Salva come JPEG
Città #
Fairfield 893
Woodbridge 603
Chandler 514
Houston 415
Ashburn 408
Seattle 394
Cambridge 311
Wilmington 299
Nyköping 290
Ann Arbor 224
Jacksonville 224
Singapore 189
Lawrence 117
Roxbury 114
Beijing 102
Nanjing 94
Bari 87
Boardman 73
Des Moines 72
Princeton 68
New York 65
Inglewood 49
Moscow 39
San Diego 38
Brooklyn 37
Brussels 37
Jakarta 31
Helsinki 29
Munich 27
Santa Clara 27
London 26
Nanchang 25
Nuremberg 25
Shenyang 24
Los Angeles 21
Dong Ket 20
Norwalk 20
Tianjin 18
Hebei 17
Jiaxing 17
Guangzhou 16
Paris 15
Toronto 15
Hong Kong 14
Bisceglie 13
Shanghai 13
Wuhan 12
Marseille 10
Mottola 10
North Bergen 10
Changsha 9
Pune 9
Redwood City 9
Rome 8
Brno 7
Dearborn 7
Lviv 7
Milan 7
Chicago 6
Frankfurt am Main 6
Jinan 6
Taranto 6
Catania 5
Dublin 5
Hefei 5
Jeddah 5
Monmouth Junction 5
San Mateo 5
São Paulo 5
Vienna 5
Washington 5
Xi'an 5
Augusta 4
Belo Horizonte 4
Falkenstein 4
Garden City 4
Grottaglie 4
Hanover 4
Jinhua 4
Kilburn 4
Ningbo 4
Ottawa 4
Porto Alegre 4
Senigallia 4
Amsterdam 3
Ardabil 3
Lauterbourg 3
Melbourne 3
Rio de Janeiro 3
Romola 3
Salt Lake City 3
San Francisco 3
Tashkent 3
Trani 3
Villacidro 3
Wuxi 3
Yiwu 3
Zhengzhou 3
Algiers 2
Bazhou 2
Totale 6.442
Salva come PNG Salva come JPEG
Nome #
Long-term cardiac safety and tolerability of fingolimod in multiple sclerosis: A postmarketing study 140
Prognostic indicators in pediatric clinically isolated syndrome 139
Fingolimod versus interferon beta/glatiramer acetate after natalizumab suspension in multiple sclerosis 138
The Cost of Patients With Relapsing-Remitting Multiple Sclerosis Who Develop Neutralizing Antibodies While Treated With Interferon Beta 131
A rare association between multiple sclerosis and Charcot-Marie-Tooth type 1B 119
Gender differences in safety issues during Fingolimod therapy: Evidence from a real-life Relapsing Multiple Sclerosis cohort 116
Adhesion molecules and matrix metalloproteinases in Multiple Sclerosis: effects induced by Interferon-beta 114
The cost of relapsing-remitting multiple sclerosis patients who develop neutralizing antibodies during interferon beta therapy 114
Age-related changes of serum N-acetyl-aspartate in healthy controls. 113
Lymphocyte subsets as biomarkers of therapeutic response in Fingolimod treated Relapsing Multiple Sclerosis patients 113
RELATIONSHIP OF COGNITIVE PERFORMANCES AND EMPLOYMENT STATUS IN PEOPLE WITH RELAPSING MULTIPLE SCLEROSIS 111
null 109
Impact of natalizumab on cognitive performances and fatigue in relapsing multiple sclerosis: a prospective, open-label, two years observational study. 106
Retrospectively acquired cohort study to evaluate the long-term impact of two different treatment strategies on disability outcomes in patients with relapsing multiple sclerosis (RE.LO.DI.MS): data from the Italian MS Register 105
Long-Term Data of Efficacy, Safety, and Tolerability in a Real-Life Setting of THC/CBD Oromucosal Spray-Treated Multiple Sclerosis Patients 103
Exploratory analysis of predictors of patient adherence to subcutaneous interferon beta-1a in multiple sclerosis: TRACER study 103
"Better explanations" in multiple sclerosis diagnostic workup: A 3-year longitudinal study 103
Lymphocyte count and body mass index as biomarkers of early treatment response in a multiple sclerosis dimethyl fumarate-treated cohort 102
Cerebrospinal fluid neurofilament light levels mark grey matter volume in clinically isolated syndrome suggestive of multiple sclerosis 101
Associations between cognitive impairment at onset and disability accrual in young people with multiple sclerosis 101
Age-related disability in multiple sclerosis 96
Review of interferon beta-1b in the treatment of early and relapsing multiple sclerosis. 94
Sativex in resistant multiple sclerosis spasticity: Discontinuation study in a large population of Italian patients (SA.FE. study) 94
Mitoxantrone prior to interferon beta-1b in aggressive relapsing multiple sclerosis: a 3-year randomised trial. 93
Predictors of long-term disability accrual in relapse-onset multiple sclerosis 91
BLOOD MMP-9 AND SICAM-1 AS MARKERS OF RIFN-B TREATMENT EFFICACY IN RELAPSING-REMITTING MS 90
The frequency of CSF oligoclonal banding in multiple sclerosis increases with latitude. 90
Early prediction of the long term evolution of multiple sclerosis: the Bayesian Risk Estimate for Multiple Sclerosis (BREMS) score. 88
Natural history of multiple sclerosis: have available therapies impacted long-term prognosis? 86
Long-term disability trajectories in relapsing multiple sclerosis patients treated with early intensive or escalation treatment strategies 86
DMTs and Covid-19 severity in MS: a pooled analysis from Italy and France 85
Predictors of disability worsening in clinically isolated syndrome 83
Analisi longitudinale dei livelli sierici di ICAM-1 solubile e dei subsets di linfociti T in pazienti con Sclerosi Multipla a decorso remittente in trattamento con IFNb-1b 82
Atypical forms of Multiple Sclerosis or different phases of a same disease? 81
A multicenter, observational, prospective study of self- and parent-reported quality of life in adolescent multiple sclerosis patients self-administering interferon-β1a using RebiSmart™-the FUTURE study. 81
Long-term comparative analysis of no evidence of disease activity (NEDA-3) status between multiple sclerosis patients treated with natalizumab and fingolimod for up to 4 years 81
Epidural analgesia and cesarean delivery in multiple sclerosis post-partum relapses: the Italian cohort study. 78
The role of neutralizing antibodies to interferon-β as a biomarker of persistent MRI activity in multiple sclerosis: a 7-year observational study 77
PBMC of Multiple Sclerosis Patients Show Deregulation of OPA1 Processing Associated with Increased ROS and PHB2 Protein Levels 77
Breastfeeding is not related to postpartum relapses in multiple sclerosis. 75
Patient expression of emotions and neurologist responses in first multiple sclerosis consultations 74
null 73
Postmarketing evidence of disease-modifying drugs in multiple sclerosis 73
Low serum urate levels are associated to female gender in multiple sclerosis patients. 72
null 71
null 68
null 68
null 67
CHANGES OF SERUM ICAM-1 AND MMP-9 INDUCED BY RIFNB-1B TREATMENT IN RELAPSING-REMITTING MS 65
The transition from relapsing-remitting MS to irreversible disability: clinical evaluation. 65
null 65
null 64
null 62
Variations of the perforin gene in patients with multiple sclerosis. 62
Lesion load may predict long-term cognitive dysfunction in multiple sclerosis patients 61
Guidelines on the clinical use for the detection of neutralizing antibodies (NAbs) to IFN beta in multiple sclerosis therapy: report from the Italian Multiple Sclerosis Study group. 61
Durvalumab and multiple sclerosis: a causal link or simple unmasking? 61
null 60
null 58
null 58
CHANGES OF SERUM SOLUBLE ICAM-1 AND MATRIX METALLOPROTEINASE-9 DURING INTERFERON BETA-1B TREATMENT IN RR MS 57
Interferon beta in relapsing-remitting multiple sclerosis: an independent postmarketing study in southern Italy 57
Characteristics and treatment of Multiple Sclerosis-related trigeminal neuralgia: An Italian multi-centre study 56
Seroconversion and indolent course of COVID-19 in patients with multiple sclerosis treated with fingolimod and teriflunomide 56
Transition to secondary progression in relapsing-onset multiple sclerosis: Definitions and risk factors 56
null 55
null 55
Pregnancy decision-making in women with multiple sclerosis treated with natalizumab: I: Fetal risks 55
Harmonization of real-world studies in multiple sclerosis: Retrospective analysis from the rirems group 55
Pregnancy and fetal outcomes after Glatiramer Acetate exposure in patients with multiple sclerosis: a prospective observational multicentric study 54
The Italian Multiple Sclerosis Database Network (MSDN): the risk of worsening according to IFNbeta exposure in multiple sclerosis. 54
Defining the course of tumefactive multiple sclerosis: a large retrospective multicentre study 54
RIFNB DOWNREGULATES TNFA-INDUCED ICAM-1 EXPRESSION ON BRAIN MICROVASCULAR ENDOTHELIAL CELLS (BEMC) AND INCREASES SERUM SOLUBLE ICAM-1 (SICAM-1) IN RR MS 53
Geographical variations in sex ratio trends over time in multiple sclerosis. 53
null 53
null 51
ADHESION MOLECULES AND MATRIX METALLOPROTEINASES IN MS: EFFECTS INDUCED BY INTERFERON BETA 51
Modificazioni dei livelli sierici di ICAM-1 solubile (sICAM.1), e Gelatinasi A e B e sottopopolazioni T-linfocitarie di sangue periferico indotte dal trattamento con interferone-beta-1b (IFN-BETA-1B) in pazienti con Sclerosi Multipla (SM) Relapsing-Remitting (RR): Relazione con la produzione di anticorpi neutralizzanti anti-interferone (NABs) 50
null 50
null 50
Effect of cladribine on neuronal apoptosis: New insight of in vitro study in multiple sclerosis therapy 50
COVID-19 Severity in Multiple Sclerosis: Putting Data Into Context 50
Magnetoencephalography and high‐density electroencephalography study of acoustic event related potentials in early stage of multiple sclerosis: A pilot study on cognitive impairment and fatigue 50
Pregnancy decision-making in women with multiple sclerosis treated with natalizumab: II: Maternal risks 49
The differential diagnosis of multiple sclerosis: classification and clinical features of relapsing and progressive neurological syndromes. 49
The IFN beta treatment of multiple sclerosis (MS) in clinical practice: the experience at the MS Center of Bari, Italy 48
Immunomodulatory therapies delay disease progression in multiple sclerosis. 48
Cost-Effectiveness Analysis of Cannabinoid Oromucosal Spray Use for the Management of Spasticity in Subjects with Multiple Sclerosis 48
Efficacy and Safety of Oral Therapies for Relapsing-Remitting Multiple Sclerosis 48
PML risk is the main factor driving the choice of discontinuing natalizumab in a large multiple sclerosis population: results from an Italian multicenter retrospective study 48
Longitudinal Evaluation of Serum MOG-IgG and AQP4-IgG Antibodies in NMOSD by a Semiquantitative Ratiometric Method 46
Risk of multiple sclerosis relapses when switching from fingolimod to cell-depleting agents: the role of washout duration 46
Soluble Intercellular Adhesion Molecule-1 in serum and cerebrospinal fluid of demyelinating disease of the central and peripheral nervous system 45
IFNB-1B TREATMENT EFFECTS ON SOLUBLE INTERCELLULAR ADHESION MOLECULE-1 SERUM LEVELS AND T-CELL SUBSETS IN RELAPSING-REMITTING MULTIPLE SCLEROSIS PATIENTS. 12TH CONGRESS OF THE EUROPEAN COMMITTE FOR TREATMENT AND RESEARCH IN MULTIPLE SCLEROSIS (ECTRIMS) 45
Informing MS patients on treatment options: a consensus on the process of consent taking 45
Neuromyelitis optica spectrum disorders associated with systemic sclerosis: a case report and literature review 45
Changes of serum sICAM-1 and MMP-9 induced by rIFN beta-1b treatment in relapsing-remitting MS 40
Age-related gadolinium-enhancement of MRI brain lesions in multiple sclerosis. 40
VALUTAZIONE POST-MARKETING DI SICUREZZA DELL' INTERFERONE-BETA (IFN-BETA) IN PAZIENTI CON SCLEROSI MULTIPLA (SM) RELAPSING-REMITTING (RR) NELL' ITALIA MERIDIONALE. RICERCA SCIENTIFICA DELLE 38
Predictors of unemployment status in people with relapsing multiple sclerosis: a single center experience 38
Totale 7.288
Salva come PNG Salva come JPEG
Categoria #
all - tutte 44.047
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 44.047
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020395 0 0 0 0 0 0 0 0 0 126 224 45
2020/20211.390 104 80 111 113 163 100 132 101 107 166 125 88
2021/2022936 57 109 16 33 44 88 43 46 86 59 173 182
2022/20231.382 225 178 83 122 162 162 17 165 204 5 26 33
2023/2024461 57 66 28 29 37 108 13 18 8 23 6 68
2024/20251.453 133 42 180 102 75 246 257 223 133 62 0 0
Totale 8.718